Is frontline R-CHOP still the standard of care for DLBCL?
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Laurie Sehn, The University of British Columbia, Vancouver, CA, and Grzegorz Nowakowski, Mayo Clin...
18 Elo 202116min
What are the recent advances in antibody-drug conjugates for lymphoma treatment?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Catherine S. Diefenbach, Perlmutter Cancer Center, New York, US. We asked, What are the recent advances in antibody-drug conjugates for...
19 Heinä 202112min
What is the role of genetic classification in the diagnosis of DLBCL?
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Björn Chapuy, Universitätsmedizin Göttingen, Göttingen, DE, and University Hospital Tübingen, Tübi...
7 Heinä 202114min
What factors should be considered when deciding whether to refer a patient for CAR T-cell therapy?
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What factors should be considered when deciding whether to refer a pa...
30 Kesä 20217min
What does real-world data tell us about frontline treatment strategies for MCL?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell Medicine, New York, US. We asked, What does real-...
29 Kesä 202113min
Can ctDNA help inform on the suitability of auto-SCT in patients with DLBCL?
This is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the managemen...
1 Helmi 20219min
Why should we use ctDNA assessments in lymphoma diagnostics in the future?
This is the first episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management...
11 Tammi 20217min
Does ctDNA add value to current prognostic markers for identifying high-risk patients?
This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management...
7 Tammi 20215min
